Dyne Therapeutics, Inc. is a US-based pharmaceutical company with a focus on developing therapeutics for patients with genetically driven diseases. They aim to address the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. Dyne Therapeutics is working on treatments for muscle disorders such as Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. With a medium-risk ESG score of 26.0, Dyne Therapeutics is committed to making sustainable and environmentally-friendly advancements in the pharmaceutical industry.